I2Pure Corporation announced on November 12, 2026, that research conducted by its scientists has identified differences in the release and transport of molecular iodine from commonly used antiseptic formulations. The company highlighted findings published in ACS Omega showing that iodine carrier chemistry, dilution and lipid interactions can substantially influence the amount of molecular iodine transferred across a laboratory interface, challenging the assumption that conventional available-iodine measurements fully describe an antiseptic formulation’s delivery characteristics.
The announcement revisits a peer-reviewed study originally published online on November 18, 2025, rather than reporting a newly completed clinical investigation. Researchers examined five commercial povidone-iodine formulations and one dextrin-iodine complex using a model intended to investigate transport between aqueous and lipid-like environments. Their findings support further study of formulation-dependent iodine release, but they do not establish that existing povidone-iodine antiseptics are clinically ineffective.
The development is relevant to pharmaceutical formulation specialists and infection prevention researchers because iodine-based preparations remain widely used in healthcare. However, the most consequential distinction concerns what was measured: the research quantified physicochemical transport under controlled laboratory conditions, not infection rates, surgical outcomes or comparative effectiveness in patients. Translating the findings into clinical practice would require additional studies using suitable biological models and validated antimicrobial or clinical endpoints.
Why can total available iodine differ from the molecular iodine released by an antiseptic?
Povidone-iodine formulations contain iodine associated with a polymer carrier that improves solubility and acts as a reservoir for iodine species. In aqueous solution, iodine exists in a chemical equilibrium involving free molecular iodine, iodide, triiodide and carrier-associated species. These forms contribute differently to the formulation’s chemistry and determine how iodine becomes available during use.
Conventional measurements of available iodine commonly rely on titration methods that quantify iodine capable of participating in the relevant chemical reaction. This provides a useful specification for product quality and manufacturing consistency. However, the measurement does not independently determine how quickly free molecular iodine becomes available at a biological interface.
Free molecular iodine contributes importantly to the antimicrobial activity of iodophor preparations. Its concentration depends on the formulation, dilution conditions and chemical interactions with surrounding materials. As free iodine is consumed or transferred, additional iodine may be released from the carrier reservoir to restore equilibrium.
The reservoir function is central to understanding why a low instantaneous free-iodine concentration does not necessarily indicate poor antimicrobial activity. A formulation may contain a relatively small free fraction while retaining a larger quantity capable of replenishing that fraction during exposure. Consequently, the amount initially unbound should not be treated as the complete quantity potentially available for antimicrobial action over time.
I2Pure’s research focuses on the relationship between the carrier system and the transport of iodine into a lipid-like environment. Its findings suggest that formulations with identical available-iodine measurements can behave differently under the experimental conditions examined. This provides a rationale for investigating release kinetics alongside conventional concentration measurements.
The commercial implication is that future antiseptic development may benefit from a more detailed understanding of iodine availability. Nevertheless, total available iodine remains an established quality parameter, and the study does not demonstrate that existing product specifications are universally inadequate for their intended regulatory purposes.
What did the ACS Omega study establish about iodine transport across a model interface?
The research, titled Transport of Molecular Iodine From Antiseptic Iodophors across Hydrophilic-Lipophilic Interfaces: Influence of Phospholipids, was conducted by I2Pure-affiliated scientists Maggie Engert, Christopher Moses, Jack Kessler and Ilker Bayer. The study used a heptane-water interface to investigate molecular iodine movement from aqueous antiseptic preparations into a lipophilic phase. Heptane served as a simplified experimental environment rather than a direct substitute for living skin or microbial membranes.
The researchers evaluated five commercial povidone-iodine formulations and one modified dextrin-iodine complex. Each was standardised to 1% titratable iodine before testing, allowing comparisons of release behaviour under defined conditions. Iodine transfer was assessed using spectroscopic measurements and chemical titration.
Under undiluted conditions, one representative povidone-iodine sample transferred approximately 4% of its available iodine into the heptane phase. This figure describes transport under a particular laboratory condition and should not be interpreted as showing that only 4% of the antiseptic can participate in antimicrobial activity during clinical use. Other formulations and experimental conditions produced different transfer results.
The researchers found that dilution substantially altered iodine transport. For the representative sample, a tenfold dilution increased the fraction transferred to the lipophilic phase to approximately 69%, even though the total quantity of iodine present in the diluted preparation was lower. This illustrates why changes in chemical equilibrium can influence both the proportion and absolute amount of iodine transferred.
The experimental results also showed differences between the polymer systems. The modified dextrin-iodine complex demonstrated more extensive iodine release under several tested conditions than the conventional povidone-iodine samples. These observations suggest that carrier chemistry can influence transport behaviour, although the findings cannot establish clinical superiority without additional comparative testing.
The study provides a useful physicochemical explanation for why antiseptic performance cannot always be inferred from one concentration measurement. Its strongest contribution is the direct investigation of release and partitioning under defined laboratory conditions. The next scientific requirement is to establish how those measurements relate to antimicrobial efficacy and tolerability under realistic conditions.
Why does iodine dilution produce different release behaviour?
Dilution changes the concentration of iodine species and alters the interactions between iodine and the carrier polymer. These changes can shift the chemical equilibrium, allowing a greater proportion of iodine to become available as free molecular iodine under certain conditions. This phenomenon has been recognised in earlier research on povidone-iodine formulations.
The I2Pure study provides additional quantitative information about how dilution influences iodine transfer across a model interface. Researchers found that dilution could increase the fraction of iodine moving into the lipophilic phase, while the response depended on the formulation being tested. The results therefore support the importance of both concentration and carrier chemistry.
However, increasing the proportion of iodine released is not equivalent to increasing the total amount delivered under every condition. A more diluted preparation contains less total iodine, which can affect the quantity available for continued release. The appropriate balance depends on the intended application, contact time and formulation characteristics.
Dilution can also affect product stability, antimicrobial performance and compatibility with tissues. A preparation that shows favourable laboratory transport after dilution may not retain those characteristics during storage or prolonged use. Product-specific studies are therefore necessary before drawing conclusions about practical formulation changes.
Healthcare guidance has long recognised that iodine formulations may behave differently after dilution and that iodophors should be prepared according to manufacturers’ directions. The United States Centers for Disease Control and Prevention has previously discussed the relationship between dilution and iodine antimicrobial activity. I2Pure’s findings add mechanistic detail to this established area rather than discovering the dilution effect for the first time.
The study should not be interpreted as an instruction to dilute commercial antiseptics independently. Changes to a validated formulation could alter performance and safety characteristics in ways not addressed by the laboratory investigation. Any revised dilution protocol would require appropriate product-specific evidence and regulatory consideration.
How do phospholipids influence molecular iodine transport?
The researchers also investigated how phospholipids affect iodine movement across the experimental interface. Phospholipids are important components of biological membranes and contain molecular structures capable of interacting with iodine. Their inclusion allowed the investigators to examine whether lipid composition influences iodine partitioning and transfer.
The study found that phospholipid-containing conditions enhanced iodine transport in the evaluated model. The researchers described chemical interactions consistent with charge-transfer processes involving molecular iodine and lipid components. These findings support further investigation of the relationship between iodine release and its interaction with biological interfaces.
However, a phospholipid-rich solvent system does not reproduce the full structure and function of a bacterial cell membrane or human tissue. Living biological environments contain proteins, carbohydrates, complex lipid arrangements and other components that can influence antimicrobial activity. Observed transport across a simplified laboratory interface therefore cannot independently establish how iodine behaves in clinical use.
The study also used mathematical models to describe release kinetics. Weibull and Michaelis-Menten approaches produced high coefficients of determination, with reported values exceeding 0.988. These results indicate that the models fitted the measured experimental data closely under the tested conditions.
A strong mathematical fit does not establish that the models accurately predict antimicrobial performance in patients. Their utility depends on whether the underlying assumptions remain appropriate when applied to different formulations and biological environments. Further validation would be necessary before using these models to support clinical claims.
The findings are nevertheless relevant to formulation development because they provide quantitative tools for comparing iodine release behaviour. Researchers may be able to use such approaches to investigate how formulation composition affects transport. Their eventual value will depend on demonstrating a relationship between measured release characteristics and relevant biological outcomes.
Does the research establish that conventional povidone-iodine antiseptics are unreliable?
I2Pure’s November announcement characterises the findings as evidence of a reliability gap in conventional iodine antiseptics. The underlying study supports a narrower conclusion: available-iodine measurements alone do not capture every aspect of iodine release and transport under the experimental conditions examined. It does not demonstrate that approved or established povidone-iodine products fail to provide effective antisepsis in clinical practice.
Povidone-iodine has a long history of antimicrobial use, supported by extensive laboratory and clinical experience. Its effectiveness depends on formulation, concentration, contact time and the conditions under which it is applied. The availability of free molecular iodine is an important part of the mechanism, but antimicrobial performance cannot be reduced to one instantaneous chemical measurement.
A clinically meaningful comparison would require matched formulations assessed against relevant microorganisms under standardised conditions. Studies may also need to examine organic contamination, skin compatibility, tissue effects and the ability to reduce microbial burden under realistic application procedures. Clinical infection outcomes would require an even higher level of evidence.
The published study did not directly measure infection prevention in surgical patients, hospitalised populations or wound-care settings. It therefore cannot establish that changing the iodine carrier would reduce surgical site infections or other healthcare-associated infections. The commercial implications remain dependent on further product development and validation.
The age of the study is also relevant to evaluating the announcement. Although I2Pure highlighted the findings in November 2026, the peer-reviewed article was published in November 2025. The latest development is the company’s renewed emphasis on its potential implications for antiseptic formulation, not the publication of a new experimental dataset.
How does the iodine transport study differ from I2Pure’s recent antimicrobial research?
I2Pure’s latest announcement follows separate research publicised in October 2026 involving proprietary molecular iodine formulations tested against clinically important microorganisms. That investigation examined antimicrobial activity against bacterial and fungal strains, including selected drug-resistant pathogens. It addressed direct laboratory killing rather than the physical chemistry of iodine transport.
The two studies therefore examine different questions. The molecular transport research investigates how iodine becomes available from carrier systems, while the antimicrobial study evaluates whether selected formulations reduce recoverable microorganisms under controlled conditions. Together, they provide complementary information about formulation behaviour and laboratory antimicrobial performance.
However, the results cannot automatically be combined to establish one comprehensive clinical superiority claim. The studies used different formulations, testing methods and endpoints. A formulation that performs favourably in an iodine transport experiment is not necessarily the same product evaluated for pathogen killing, and the relationship between the measurements must be demonstrated.
The October study provided evidence of rapid antimicrobial activity for several I2Pure formulations against a range of tested pathogens. It also identified differences in performance depending on the organism and formulation. Those observations do not establish that every molecular iodine product will perform identically or that laboratory findings predict reductions in human infections.
The current research adds a mechanistic dimension to I2Pure’s development strategy. If the company can connect formulation chemistry with reproducible antimicrobial performance, that evidence could support future product optimisation. The next requirement will be demonstrating consistent performance in the specific applications for which products are intended.
What regulatory and commercial hurdles remain for next-generation iodine antiseptics?
I2Pure is developing molecular iodine technology for applications involving healthcare, wound care and broader antimicrobial uses. The company has also disclosed commercial licensing activity and manufacturing expansion. These developments provide context for its ambition to translate iodine formulation research into products and partnerships.
However, regulatory requirements differ substantially according to intended use. A topical antiseptic, a wound-care product and an environmental disinfectant may follow different regulatory pathways. Evidence supporting one formulation or use cannot automatically be extended to another.
Human compatibility is particularly important. An antiseptic intended for repeated skin application must demonstrate suitable tolerability, while products used on wounds or sensitive tissues may require additional assessment. High antimicrobial activity does not independently establish an acceptable safety profile, particularly when formulation changes influence iodine availability.
Product stability will also matter. A formulation designed to release greater quantities of free molecular iodine must maintain predictable characteristics during storage and use. Packaging, temperature, exposure to light and interactions with other ingredients may influence the final product’s performance.
For commercial partners, the value of I2Pure’s technology will depend on whether these formulation advantages can be translated into validated products that meet applicable quality and regulatory requirements. Manufacturing reproducibility, cost and compatibility with existing clinical workflows will also influence adoption. Laboratory studies can support development, but they do not replace product-specific validation.
I2Pure’s research provides useful evidence that the chemistry of iodine release deserves consideration alongside conventional concentration measurements. It also highlights why promotional claims about antiseptic reliability must remain aligned with the actual experimental evidence. The next meaningful milestone will be a controlled demonstration that a specific formulation produces superior antimicrobial or clinical outcomes under conditions relevant to its intended use.
